Cargando…

Why differentiate low molecular weight heparins for venous thromboembolism?

Detalles Bibliográficos
Autores principales:	Fareed, Jawed, Walenga, Jeanine M
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2007
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1936420/ https://www.ncbi.nlm.nih.gov/pubmed/17578577 http://dx.doi.org/10.1186/1477-9560-5-8

Ejemplares similares

Low-molecular-weight heparins in the treatment of venous thromboembolism
por: Ageno , Walter, et al.
Publicado: (2000)

The Risk of Venous Thromboembolism is Not Equal for all Patients Who Undergo Total Joint Replacement
por: Tafur, Alfonso, et al.
Publicado: (2019)

Differentiation of parenteral anticoagulants in the prevention and treatment of venous thromboembolism
por: Fareed, Jawed, et al.
Publicado: (2011)

Zika and Chikungunya Virus and Risk for Venous Thromboembolism
por: Ramacciotti, Eduardo, et al.
Publicado: (2019)

Bovine Mucosal Heparins Are Comparable to Porcine Mucosal Heparin at USP Potency Adjusted Levels
por: Jeske, Walter, et al.
Publicado: (2019)

Rivaroxaban versus Low-Molecular-Weight Heparin for Venous Thromboembolism in Gastrointestinal and Pancreatobiliary Cancer
por: Lee, Jang Ho, et al.
Publicado: (2019)

Effectiveness and Safety of Rivaroxaban and Low Molecular Weight Heparin in Cancer-Associated Venous Thromboembolism
por: Coleman, Craig I., et al.
Publicado: (2023)

Unfractionated heparin or low-molecular-weight heparin for venous thromboembolism prophylaxis after hepatic resection: A meta-analysis
por: Zhang, Wentao, et al.
Publicado: (2022)

Cancer-Associated Venous Thromboembolism: A Practical Review Beyond Low-Molecular-Weight Heparins
por: Smrke, Alannah, et al.
Publicado: (2017)

Comparison of Low-Molecular-Weight Heparins Prepared From Ovine Heparins With Enoxaparin
por: Chen, Jianle, et al.
Publicado: (2019)

Advances in Heparins and Related Research. An Epilogue
por: Fareed, Jawed, et al.
Publicado: (2018)

Prevention and treatment of venous thromboembolism with low-molecular-weight heparins: Clinical implications of the recent European guidelines
por: Prandoni, Paolo
Publicado: (2008)

Prophylaxis of cancer-associated venous thromboembolism with low-molecular-weight heparin-tinzaparin: Real world evidence
por: Christopoulou, Athina, et al.
Publicado: (2022)

Porcine Mucosal Heparin Shortage Crisis! What Are the Options?
por: Fareed, Jawed, et al.
Publicado: (2019)

Update on the safety and bioequivalence of biosimilars – focus on enoxaparin
por: Jeske, Walter, et al.
Publicado: (2013)

The Efficacy of Low Molecular Weight Heparin for the Prevention of Venous Thromboembolism after Hip Fracture Surgery in Korean Patients
por: Kim, Kwang-Kyoun, et al.
Publicado: (2016)

Evaluation of the safety and effectiveness of direct oral anticoagulants and low molecular weight heparin in gastrointestinal cancer-associated venous thromboembolism
por: Recio-Boiles, Alejandro, et al.
Publicado: (2019)

COVID-19, Low-Molecular-Weight Heparin, and Hemodialysis
por: Perna, Alessandra F., et al.
Publicado: (2020)

Effect of hydrocolloid dressing combined with low molecular weight heparin and calcium on scar hyperplasia in burn patients with venous thromboembolism
por: Li, Chengzhi, et al.
Publicado: (2023)

Heparan sulphate inhibition of cell proliferation induced by TGFβ and PDGF
por: Silber, lan E., et al.
Publicado: (1993)

Emphasis on the Role of PF4 in the Incidence, Pathophysiology and Treatment of Heparin Induced Thrombocytopenia
por: Prechel, M Margaret, et al.
Publicado: (2013)

Comparative Pharmacokinetic Profile of 3 Batches of Ovine Low-Molecular-Weight Heparin and 1 Batch of Branded Enoxaparin
por: Jeske, Walter, et al.
Publicado: (2018)

Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist
por: Bamber, Luke, et al.
Publicado: (2015)

Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences
por: Lanitis, Tereza, et al.
Publicado: (2017)

Biomarkers of Venous Thromboembolism Recurrence after Discontinuation of Low Molecular Weight Heparin Treatment for Cancer-Associated Thrombosis (HISPALIS-Study)
por: Otero, Remedios, et al.
Publicado: (2022)

Can We Improve on the Rapid Assessment of Clinically Relevant Levels of Direct Acting Oral Anticoagulants (DOAC)?
por: Walenga, Jeanine M.
Publicado: (2022)

Low-molecular-weight heparins for the prevention of recurrent venous thromboembolism in patients with cancer: A systematic literature review of efficacy and cost-effectiveness
por: Dranitsaris, George, et al.
Publicado: (2017)

The safety of low-molecular-weight heparins in the prevention of venous thromboembolism in surgically-treated cancer patients: results of a multicentre observational study
por: Olesiński, Tomasz, et al.
Publicado: (2017)

Higher Adherence to Treatment With Low-Molecular-Weight-Heparin Nadroparin Than Enoxaparin Because of Side Effects in Cancer-Associated Venous Thromboembolism
por: van der Wall, Sake J., et al.
Publicado: (2018)

Posterior Fossa Hemorrhage Following the Use of Low-Molecular-Weight Heparin: Lessons Learned and Recommendations for the Treatment and Prophylaxis of Postoperative Venous Thromboembolism
por: Naeem, Komal, et al.
Publicado: (2021)

Strategies involving low-molecular-weight heparin for the treatment and prevention of venous thromboembolism in patients with obesity: A systematic review and meta-analysis
por: Liu, Junjie, et al.
Publicado: (2023)

Low Molecular Weight Heparin Treatment Patterns and Outcomes in Cancer Patients with Acute Venous Thromboembolism: A Nationwide Cohort Study in France
por: Bertoletti, Laurent, et al.
Publicado: (2023)

The efficacy and safety of low-molecular-weight heparin and unfractionated heparin in the treatment of cerebral venous sinus thrombosis
por: Afshari, Daryoush, et al.
Publicado: (2015)

Aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in orthopaedic trauma patients: A patient-centered randomized controlled trial
por: Haac, Bryce E., et al.
Publicado: (2020)

Comparison Between Non–vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism
por: Chen, Dong-Yi, et al.
Publicado: (2021)

Risk‐Stratified Venous Thromboembolism Prophylaxis after Total Joint Arthroplasty: Low Molecular Weight Heparins and Sequential Aspirin vs Aggressive Chemoprophylaxis
por: Peng, Hui‐ming, et al.
Publicado: (2021)

Rivaroxaban Versus Low-Molecular-Weight Heparins in a Broad Cohort of Patients With Cancer-Associated Venous Thromboembolism: An Analysis of the OSCAR-US Program
por: Caroti, Kimberly Snow, et al.
Publicado: (2023)

What's new in emergencies, trauma, and shock? Heparin in severe traumatic brain injury: Beyond venous thromboembolism prevention?
por: Masotti, Luca, et al.
Publicado: (2014)

Safety of heparin prophylaxis for venous thromboembolism in patients with neurotrauma
por: Puri, G, et al.
Publicado: (2010)

Low-Molecular-Weight Heparin Use in a Case of Noncardiogenic Multifocal Perinatal Thromboembolic Stroke
por: Saxonhouse, Matthew A., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_mvbvom25noa34jtt881oeh3hi5